Life insurance and early cancer detection

REGISTER

Nearly two million people are expected to be diagnosed with cancer in the US this year. While that number is staggering, we know how important early detection and diagnosis are when it comes to favorable outcomes. Join leaders from John Hancock and GRAIL to explore the science behind Galleri^® — a multi-cancer, early detection test — and discuss why the life insurance industry is well positioned to make this groundbreaking test more accessible. John Hancock was first life insurance carrier to make Galleri available to customers, and recently expanded access to the test to thousands more. In this interactive session we’ll cover:

• What the Galleri test is and how it works
• Why GRAIL sought out John Hancock to help expand access to the technology
• How John Hancock is making Galleri available to Vitality PLUS life insurance customers, including your clients
• How you can leverage access to the Galleri test during sales conversations

PRESENTERS

Matthew M. Gibson, ACS
Head of Behavioral Insurance Market Enablement
John Hancock

Wayne Lilyestrom, PhD
Field Medical Director, Enterprise Channel
GRAIL

Horacio Herrera-Fajer
Head of Life Insurance Partnerships
GRAIL